In a report released yesterday, Yaron Werber from TD Cowen maintained a Buy rating on Amgen (AMGN – Research Report), with a price target of $389.00.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Yaron Werber’s rating is based on Amgen’s strong financial performance and promising future prospects. The company has recently reported a solid quarter with higher-than-expected revenue and earnings per share, driven by key products like Amjevita, Repatha, Blincyto, and Krystexxa. This success is complemented by the positive outlook for 2025, with expected revenue and non-GAAP EPS guidance exceeding consensus estimates, indicating robust growth across Amgen’s core commercial franchises.
Furthermore, Amgen’s pipeline is poised for significant advancements, which are likely to act as catalysts for future growth. The company is making strides in the obesity sector, with MariTide entering Phase 3 trials and more data expected later this year. Despite a clinical hold on AMG 513, management is confident in a resolution. Additionally, upcoming data releases for rocatinlimab and bemarituzumab are anticipated to boost investor interest in Amgen’s innovative projects, underpinning Werber’s Buy rating.
Werber covers the Healthcare sector, focusing on stocks such as Amgen, Ultragenyx Pharmaceutical, and Genmab. According to TipRanks, Werber has an average return of 8.5% and a 50.54% success rate on recommended stocks.
In another report released on January 30, Piper Sandler also assigned a Buy rating to the stock with a $310.00 price target.